Skip to main content
. Author manuscript; available in PMC: 2016 Jun 18.
Published in final edited form as: Chem Biol. 2015 Jun 4;22(6):755–763. doi: 10.1016/j.chembiol.2015.05.009

Figure 4. ARV-825 leads to a superior effect on BL cells proliferation suppression than BRD4 inhibitors.

Figure 4

(A) Various BL cell lines were seeded at 50000 cells/100ul in 96-well plates and then treated with increasing doses of ARV-825, JQ1 and OTX015; relative proliferation was determined by CellTiter-Glow (CTG) assay 72 hours later.

(B) ARV-825 leads to longer lasting proliferation suppression than small molecule inhibitors Namalwa cells were treated for 24 hours with ARV-825 (0.1 µM), JQ1 (1.0 µM) and OTX015 (1.0 µM), followed by three washes to remove compounds, and re-seeded in fresh medium in 96-well plate, relative proliferation was determined by CTG assay at 24 hours and 48 hours after re-seeding.

(C) Pomalidomide partially rescued the effect on proliferation suppression by ARV-825 treatment. Different BL cell lines were treated with ARV-825 (0.01 µM on left panel or 0.1 µM on right panel) alone, or together with pomalidomide (1.0 µM or 10.0 µM) for 72 hours, relative cell proliferation was determined by CTG assay.

(D) Pomalidomide does not have significant effect on BL cell proliferation. Different BL cell lines were treated with increasing doses of pomalidomide (up to 10.0 µM) for 72 hours, relative proliferation was determined by CTG assay.